Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinations work synergistically only in cancer cells and...

Descripción completa

Detalles Bibliográficos
Autores principales: Uitdehaag, Joost C. M., de Roos, Jeroen A. D. M., van Doornmalen, Antoon M., Prinsen, Martine B. W., Spijkers-Hagelstein, Jill A. P., de Vetter, Judith R. F., de Man, Jos, Buijsman, Rogier C., Zaman, Guido J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446296/
https://www.ncbi.nlm.nih.gov/pubmed/26018524
http://dx.doi.org/10.1371/journal.pone.0125021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446296/
https://www.ncbi.nlm.nih.gov/pubmed/26018524
http://dx.doi.org/10.1371/journal.pone.0125021

Ejemplares similares